Genentech Raptiva Script Growth Impacted By Enbrel Psoriasis Indication
This article was originally published in The Pink Sheet Daily
The number of "statements of medical necessity" for new Raptiva patients declined by 1,000 during the second quarter. Amgen's Phase IV trial for Enbrel could take more than 4,000 patients out of the psoriasis market.
You may also be interested in...
The company calls on 3,500 dermatologists for its psoriatic arthritis indication; Amgen hopes to increase promotion to 9,000 dermatolgists.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products